Published in PLoS One on March 11, 2013
Individuals with autism spectrum disorder show abnormalities during initial and subsequent phases of precision gripping. J Neurophysiol (2014) 0.92
Prehension synergies and hand function in early-stage Parkinson's disease. Exp Brain Res (2014) 0.89
Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy. Hum Brain Mapp (2014) 0.89
Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease. Mov Disord (2015) 0.81
Cell death, clearance and immunity in the skeletal muscle. Cell Death Differ (2016) 0.81
Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor. Hum Brain Mapp (2016) 0.80
Deficient grip force control in schizophrenia: behavioral and modeling evidence for altered motor inhibition and motor noise. PLoS One (2014) 0.76
Memory-guided force output is associated with self-reported ADHD symptoms in young adults. Exp Brain Res (2016) 0.76
Deficits in inhibitory force control in young adults with ADHD. Neuropsychologia (2017) 0.75
Validation and reliability of a modified sphygmomanometer for the assessment of handgrip strength in Parkinson's disease. Braz J Phys Ther (2015) 0.75
Grip force modulation characteristics as a marker for clinical disease progression in individuals with Parkinson disease: case-control study. Phys Ther (2014) 0.75
Memory-guided force control in healthy younger and older adults. Exp Brain Res (2017) 0.75
Inhibition and the right inferior frontal cortex. Trends Cogn Sci (2004) 9.78
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Invited review: Aging and sarcopenia. J Appl Physiol (1985) (2003) 5.01
Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci (1999) 5.01
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology (1990) 4.41
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Longitudinal muscle strength changes in older adults: influence of muscle mass, physical activity, and health. J Gerontol A Biol Sci Med Sci (2001) 3.15
High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology (2009) 3.04
A componential analysis of task-switching deficits associated with lesions of left and right frontal cortex. Brain (2004) 2.11
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology (2001) 1.87
Noise, information transmission, and force variability. J Exp Psychol Hum Percept Perform (1999) 1.86
The relationship between speed and amplitude of the fastest voluntary contractions of human arm muscles. Exp Brain Res (1978) 1.74
Neural basis for the processes that underlie visually guided and internally guided force control in humans. J Neurophysiol (2003) 1.62
Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol (2010) 1.56
Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry (2000) 1.53
MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage (2009) 1.48
Strength in Parkinson's disease: relationship to rate of force generation and clinical status. Ann Neurol (1996) 1.47
Variability of motor unit discharge and force fluctuations across a range of muscle forces in older adults. Muscle Nerve (2005) 1.39
Trajectory control in targeted force impulses. II. Pulse height control. Exp Brain Res (1987) 1.39
Effects of deep brain stimulation and medication on bradykinesia and muscle activation in Parkinson's disease. Brain (2003) 1.34
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
Precision grip and Parkinson's disease. Brain (1998) 1.29
Variability and noise in continuous force production. J Mot Behav (2000) 1.28
Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology (2005) 1.28
The significance of sarcopenia in old age. J Gerontol A Biol Sci Med Sci (1995) 1.25
Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease. Mov Disord (2010) 1.21
Milestones in research on the pathophysiology of Parkinson's disease. Mov Disord (2011) 1.18
Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand (1995) 1.13
The preparation and production of isometric force in Parkinson's disease. Neuropsychologia (1988) 1.12
Are age-related increases in force variability due to decrements in strength? Exp Brain Res (2006) 1.11
Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain (2005) 1.09
Force control and disease severity in Parkinson's disease. Mov Disord (2005) 1.08
Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain (2012) 1.08
The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology (1995) 1.03
Pathological basal ganglia activity in movement disorders. Neuroscience (2011) 1.02
Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord (2003) 1.01
"Applause sign" helps to discriminate PSP from FTD and PD. Neurology (2005) 0.98
Milestones in atypical and secondary Parkinsonisms. Mov Disord (2011) 0.96
Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain (2005) 0.94
Grip force abnormalities in de novo Parkinson's disease. Mov Disord (2004) 0.94
A component analysis of the generation and release of isometric force in Parkinson's disease. J Neurol Neurosurg Psychiatry (1992) 0.94
Cortical and subcortical mechanisms for precisely controlled force generation and force relaxation. Cereb Cortex (2009) 0.93
Force development during target-directed isometric force production in Parkinson's disease. Neurosci Lett (2006) 0.90
Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord (2008) 0.88
Milestones in clinical neurophysiology. Mov Disord (2011) 0.86
Applause sign: is it really specific for Parkinsonian disorders? Evidence from cortical dementias. J Neurol Neurosurg Psychiatry (2011) 0.82
Technology insight: imaging neurodegeneration in Parkinson's disease. Nat Clin Pract Neurol (2008) 0.80
Imaging for early differential diagnosis of parkinsonism. Lancet Neurol (2010) 0.80
The beneficial effects of subthalamic nucleus stimulation on manipulative finger force control in Parkinson's disease. Exp Neurol (2005) 0.80
The effect of subthalamic nucleus deep brain stimulation on precision grip abnormalities in Parkinson's disease. Parkinsonism Relat Disord (2006) 0.79
Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. Parkinsonism Relat Disord (2009) 0.79
Coordination of fingertip forces during precision grasping in multiple system atrophy. Neuropsychologia (2003) 0.78
Applause sign in Alzheimer's disease: relationships to cognitive profile and severity of illness. J Neurol (2012) 0.76
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Three-dimensional locations and boundaries of motor and premotor cortices as defined by functional brain imaging: a meta-analysis. Neuroimage (2006) 2.40
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
The history of cerebral PET scanning: from physiology to cutting-edge technology. Neurology (2013) 2.04
Role of hyperactive cerebellum and motor cortex in Parkinson's disease. Neuroimage (2007) 2.03
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord (2013) 1.94
Levodopa-induced dyskinesias. Mov Disord (2007) 1.94
The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology (2008) 1.92
Proprioception and motor control in Parkinson's disease. J Mot Behav (2009) 1.79
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol (2003) 1.74
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70
Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord (2013) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Neural basis for the processes that underlie visually guided and internally guided force control in humans. J Neurophysiol (2003) 1.62
Neuropathic features in fragile X premutation carriers. Am J Med Genet A (2007) 1.56
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol (2013) 1.56
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol (2002) 1.55
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Part 1: the history of 19th century neurology and the American Neurological Association. Ann Neurol (2003) 1.54
Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol (2005) 1.48
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol (2005) 1.48
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord (2013) 1.44
Role of individual basal ganglia nuclei in force amplitude generation. J Neurophysiol (2007) 1.44
Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord (2005) 1.41
The origins of scientific cinematography and early medical applications. Neurology (2004) 1.39
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol (2010) 1.38
Effects of deep brain stimulation and medication on bradykinesia and muscle activation in Parkinson's disease. Brain (2003) 1.34
Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care (2008) 1.33
Basal ganglia mechanisms underlying precision grip force control. Neurosci Biobehav Rev (2009) 1.32
Subthalamic nucleus and internal globus pallidus scale with the rate of change of force production in humans. Neuroimage (2004) 1.31
Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord (2011) 1.31
Region of interest template for the human basal ganglia: comparing EPI and standardized space approaches. Neuroimage (2007) 1.26
Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 1.24
Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol (2003) 1.22
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease. Hum Brain Mapp (2010) 1.21
Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol (2012) 1.20
Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord (2011) 1.18
Intermittent visuomotor processing in the human cerebellum, parietal cortex, and premotor cortex. J Neurophysiol (2005) 1.18
Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease. Brain (2004) 1.18
Dystonia rating scales: critique and recommendations. Mov Disord (2013) 1.17
Contribution of Jules Froment to the study of parkinsonian rigidity. Mov Disord (2007) 1.16
Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord (2012) 1.15
Role of the basal ganglia and frontal cortex in selecting and producing internally guided force pulses. Neuroimage (2007) 1.14
Hallucinations in Parkinson disease. Nat Rev Neurol (2009) 1.13
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord (2006) 1.12
Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet (2009) 1.11
Effects of aging on the regularity of physiological tremor. J Neurophysiol (2005) 1.10
Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord (2010) 1.10
Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord (2010) 1.09
Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging. Neurobiol Aging (2010) 1.08
Effect of step training and rhythmic auditory stimulation on functional performance in Parkinson patients. Neurorehabil Neural Repair (2011) 1.08
Force control and disease severity in Parkinson's disease. Mov Disord (2005) 1.08
Effects of deep brain stimulation and medication on strength, bradykinesia, and electromyographic patterns of the ankle joint in Parkinson's disease. Mov Disord (2006) 1.07
Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord (2013) 1.07
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol (2004) 1.07
Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci (2012) 1.06
Treatment of focal dystonias with botulinum neurotoxin. Toxicon (2008) 1.06
Selective regions of the visuomotor system are related to gain-induced changes in force error. J Neurophysiol (2010) 1.05
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol (2009) 1.05
Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord (2004) 1.05
Kinematic and kinetic constraints on arm, trunk, and leg segments in target-reaching movements. J Neurophysiol (2004) 1.05
Task force report: scales for screening and evaluating tremor: critique and recommendations. Mov Disord (2013) 1.05
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study. J Int Neuropsychol Soc (2010) 1.04
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol (2010) 1.03
Effect of movement speed on limb segment motions for reaching from a standing position. Exp Brain Res (2002) 1.03